Loading...
Imaging agents for the detection of Alzheimer-related pathology have begun to make the transition from in vitro and animal studies to clinical investigations. To determine how well findings using the PET imaging agent Pittsburgh compound B (PiB) correlate with actual amyloid-beta (Aβ) deposition, researchers measured levels of binding of a fluorescent and a radiolabeled form of PiB, along with plaque burden and Aβ levels, in postmortem samples from selected brain regions of 27 individuals with Alzheimer disease (AD). The authors also performed postmortem in vitro measurements of PiB binding and Aβ in an additional patient with AD who had undergone PiB-PET imaging 10 months before death.
In the autopsy tissue, PiB binding of both fluorescent …